

# Guilherme Rabinowits

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/374828/publications.pdf>

Version: 2024-02-01

32  
papers

2,100  
citations

567281

15  
h-index

434195

31  
g-index

33  
all docs

33  
docs citations

33  
times ranked

4137  
citing authors

#	ARTICLE	IF	CITATIONS
1	Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) study.. Journal of Clinical Oncology, 2021, 39, 9547-9547.	1.6	7
2	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> . Clinical Cancer Research, 2021, 27, 5236-5247.	7.0	74
3	Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. JID Innovations, 2021, 1, 100045.	2.4	5
4	Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma. Frontiers in Medicine, 2020, 7, 198.	2.6	4
5	CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncology, 2020, 16, 11-19.	2.4	27
6	Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.. Journal of Clinical Oncology, 2020, 38, 10033-10033.	1.6	11
7	Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. European Journal of Cancer, 2019, 113, 1-9.	2.8	19
8	IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head and Neck, 2019, 41, 959-966.	2.0	8
9	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist, 2018, 23, 814-821.	3.7	30
10	A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy. Journal of AAPOS, 2018, 22, 310-312.	0.3	15
11	Consider Surgery, but Not in This Case. International Journal of Radiation Oncology Biology Physics, 2018, 100, 16.	0.8	0
12	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	9.4	392
13	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 137-145.	0.8	24
14	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine, 2018, 379, 341-351.	27.0	997
15	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist, 2017, 22, 343-350.	3.7	57
16	Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomarkers, 2017, 19, 129-136.	1.7	22
17	Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma. MBio, 2017, 8, .	4.1	100
18	Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncology, 2017, 73, 160-165.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Successful Management of a Patient with Malignant Thyroid Teratoma. <i>Thyroid</i> , 2017, 27, 125-128.	4.5	21
20	Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 191.	2.8	42
21	Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4803-4807.	2.0	14
22	Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers. <i>Journal of Oncology Practice</i> , 2016, 12, e77-e82.	2.5	9
23	Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. <i>Head and Neck</i> , 2016, 38, E1618-24.	2.0	7
24	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <i>British Journal of Cancer</i> , 2016, 115, 252-260.	6.4	66
25	Merkel Cell Carcinoma: A Population Analysis on Survival. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1247-1257.	4.9	57
26	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2939-2949.	7.0	51
27	Merkel Cell Carcinoma Presenting as Subcutaneous Breast Masses: An Uncommon Presentation of a Rare Neuroendocrine Neoplasm. <i>Breast Journal</i> , 2016, 22, 113-115.	1.0	12
28	Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6052-6052.	1.6	1
29	Differences between gene mutation profile and outcome of Merkel cell polyomavirus (MCPyV) positive and negative Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9577-9577.	1.6	0
30	Update on the Biology and Clinical Management of Merkel Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e405-e410.	3.8	3
31	Systemic Therapy for Merkel Cell Carcinoma: Whatâ€™s on the Horizon?. <i>Cancers</i> , 2014, 6, 1180-1194.	3.7	14
32	Optimizing smoking cessation resource awareness among patients and providers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 85-85.	1.6	2